Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study

被引：0
|
作者：
Pham, T. [1 ]
Ren, P. [1 ]
Parnes, J. R. [2 ]
Griffiths, J. M. [1 ]
机构：
[1] MedImmune, Gaithersburg, MD USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2677
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study
    Corren, J.
    Garcia Gil, E.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [2] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Karpefors, Martin
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1 - 10
  • [3] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [4] Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, Claire
    Corren, Jonathan
    Salapa, Kinga
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 91 - 99
  • [5] Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    [J]. ALLERGY, 2020, 75 : 17 - 18
  • [6] Incidence Of Infections In Patients With Severe, Uncontrolled Asthma Treated With Tezepelumab: A Pooled Analysis Of The Phase 2b PATHWAY And Phase 3 NAVIGATOR Studies
    Menzies-Gow, Andrew
    Corren, Jonathan
    Ambrose, Chris
    Hunter, Gillian
    Fitzpatrick, Sherahe
    Hagberg, Anette
    Ponnarambil, Sandhia
    Martin, Neil
    Molfino, Nestor
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB16 - AB16
  • [7] Efficacy of Tezepelumab in Patients with Moderate-to-Severe, Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies
    Ambrose, Chris
    Menzies-Gow, Andrew
    Cook, Bill
    Hellqvist, Asa
    Roseti, Stephanie
    Molfino, Nestor
    Llanos-Ackert, Jean-Pierre
    Colice, Gene
    Corren, Jonathan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB16 - AB16
  • [8] Efficacy of Tezepelumab in Patients with Moderate-to-Severe Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies
    Corren, J.
    Menzies-Gow, A.
    Ambrose, C.
    Cook, W.
    Hellquist, A.
    Roseti, S.
    Molfinao, N.
    Lanos-Ackert, P. J.
    Colice, G.
    [J]. PNEUMOLOGIE, 2022, 76 : S14 - S14
  • [9] The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial
    Corren, J.
    Chen, S.
    Callan, L.
    Garcia Gil, E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [10] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345